Kornimate/medical-research-clean huggingface dataset:
evaluation of perioperative lung ultrasound scores (lus) in living donor nephrectomy surgeries

Conditions: Atelectasis, Postoperative; Pulmonary Complication

Summary: living donor nephrectomy surgeries can be performed in lateral position with laparoscopic technique which necessitates pneumoperitoneum. considering the position and the pneumoperitoneum, lungs can be affected macroscopically. in this study, it is aimed to observe whether lungs are affected by the aforementioned entities. the hypothesis is based on possible deterioration of the lungs due to the physical features of laparoscopic nephrectomy. lung ultrasound score (lus) will be used to evaluate the actual condition of lungs. accordingly, one hemithorax is consisted of 6 different zones, and depending on the existence of vertical b lines (that refers to atelectasis and consolidation) each zone is scored 0 to 3. higher scores reflect worse lung conditions that is associated with the severity of atelectasis. the lus will be performed at three time points that are 5 minutes after intubation (t1), at the end of surgery and before extubation (t2), and at 30th minute in the postanesthesia care unit (t3). primary outcome will be the difference between t1 and t3, secondary outcomes will include perioperative blood gas analyses, intraoperative mechanic ventilator parameters, intraoperative total amount of fluid given, postoperative pulmonary complications.


Eligibility criteria:
inclusion criteria: * \>18 years of age * kidney donors * nephrectomy for transplantation * laparoscopic surgery exclusion criteria: * chronic obstructive pulmonary disease grade iii-iv * existing structural lung disease (eg. interstitial lung disease) * pulmonary hypertension (\>25 mmhg)
difference between pressing and vacuum techniques in fabrication of orthodontic aligners in cases with crowding: a cross-sectional study

Conditions: Orthodontic Aligners

Summary: this cross sectional study is aiming to compare 2 methods of clear aligner fabrication.


Eligibility criteria:
inclusion criteria: * maxillary arch with crowding. * full permanent dentition. exclusion criteria: * missing teeth. * dental restorations.
thigh pain after total knee arthroplasty (tka)

Conditions: Osteoarthritis, Knee

Summary: the purpose of this research study is to evaluate the cause of thigh pain after knee replacement. different surgical techniques will be used to help determine the cause of thigh pain, and all surgical techniques are accepted and produce good clinical results.

this research study will be a randomized study in which patients volunteer participate. "randomized" means the patients who received the new treatment are chosen at random, similar to flipping a coin. several factors have been identified as possible sources of thigh pain after surgery: use of a tourniquet around the thigh to control bleeding during surgery; use of an intramedullary rod during surgery or quadriceps muscle strain. participants will be randomized into surgical groups that use/do not use a tourniquet and use/do not use intramedullary rod during surgery. a subset of participants in all surgical groups will have a mri to look for quadriceps muscle strain.

Eligibility criteria:
inclusion criteria: * subjects undergoing total knee arthroplasty for osteoarthritis * adult patients (age 18 years or older) * written informed consent * ability to speak, read and write english or spanish exclusion criteria: * inability to speak, read and write english or spanish * evidence of malignant disorder/neoplasm in past 60 months * contraindication for removal of infrapatellar fat pad * history of smoking and not committed to give up * chronic skin conditions * connective, metabolic or skin disease * evidence of active infection * pregnancy or lactating for female subjects * current corticosteroid use * immunosuppressive medication * renal failure (creatine \> 1.8 mg/dl) * hepatic failure (ast, alt \> 2x normal values; bilirubin \> 2 mg/dl) * inflammatory joint diseases of the knee that indicate additional, conflating therapies * joint infection within the past 6 months * no prisoners or mentally disabled persons * no workers' compensation cases

Keywords: knee joint replacement total knee
once-daily amikacin plus cloxacillin in febrile neutropenic children

Conditions: Neutropenia; Cancer; Fever

Summary: once-daily dose administration of aminoglycoside in adults is effective and economical. however, its value in febrile neutropenic children, especially in thailand, is less well researched. in the area where pseudomonas aeruginosa prevalence in febrile neutropenic children is low, the combination of cloxacillin and amikacin is an appropriate approach. this study would like to compare the efficacy and safety including cost between these two amikacin administrations (once-daily or twice-daily) in combination with cloxacillin as an empirical therapy in febrile neutropenic children. hypothesis: once-daily amikacin plus cloxacillin can be used to treat febrile neutropenic children in khon kaen, thailand.

fever: a single oral temperature of \>/= 38.3 degrees c; or \>/= 38.0 degrees c for \>/= 1 hour. neutropenia: neutrophil count, \< 500/cu mm or \<1,000/cu mm with a predicted decrease to \<500/mm3.

Eligibility criteria:
inclusion criteria: * aged 1 year - 14 years * a single oral temperature of \>/= 38.3 degrees c; or \>/= 38.0 degrees c for \>/= 1 hour. * neutropenia: neutrophil count, \< 500/cu mm or \<1,000/cu mm with a predicted decrease to \<500/mm3. * during the course of chemotherapy exclusion criteria: * history of amikacin or cloxacillin allergy * creatinine clearance \< 30 ml/min/m2 * central nervous system infection: meningitis or brain abscess * history of hearing abnormality * severely ill: shock * chronic liver diseases or sgpt \> 10 times of upper normal limit * received aminoglycoside within 14 days prior to enrolment * received any intravenous antibiotics within 7 days * cancer which is newly diagnosed or relapsed

Keywords: febrile neutropenia once-daily amikacin cloxacillin children
relationship between dietary protein intake and fatal and non-fatal health outcomes

Conditions: Cardiovascular Diseases; Cancer; All-cause Mortality

Summary: the aim of the current study was to clarify the relationship between protein intake and health by using a very large, general population cohort study, uk biobank, to study the associations between reported protein intake (expressed in g/day, g/kg/day and % of total energy intake) and three health outcomes (all-cause mortality, incidence cvd and cancer).


Eligibility criteria:
inclusion criteria: * none exclusion criteria: * none
caffeine as a therapy for parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease is a common neurodegenerative disorder in which patients experience progressive motor disability and many disabling non-motor symptoms. recent studies have consistently found that people who do not use caffeine are at higher risk of developing parkinson's disease. this suggests that caffeine may have potential as a treatment for pd. in a pilot study of caffeine for daytime sleepiness in pd, there was evident benefit on the motor manifestations of disease. there have been other lines of evidence that have suggested caffeine could be useful in pd. this study is to evaluate the efficacy of caffeine 200 mg bid vs matching placebo for motor and non-motor aspects of disease. this will be in three stages. in the first six-month stage, medications will be held constant, to see whether caffeine does have motor benefits. then we will perform a four-year extension stage to define if the effects of caffeine persist (or even magnify), and to see if caffeine helps reduce dose of other pd meds and/or prevents their side effects. finally, we will finish with a six-month stage in which we will place all patients on caffeine - this will allow us to assess caffeine's use in later disease, but more importantly, will assess whether early use of caffeine produces long term changes beyond its immediate effects.


Eligibility criteria:
inclusion criteria: all patients must have idiopathic pd diagnosed as parkinsonism according to the uk brain bank criteria, and pd considered the likeliest underlying cause according to the treating physician. other inclusion criteria include: 1. pd diagnosis: between 6 months and 8 years 2. hoehn and yahr stage i-iii 3. age at least 45 and less than 75 (to optimize survival over the 5-year trial). 4. receiving symptomatic therapy for pd for at least 6 months. dose must have been stable over the previous 3 months. exclusion criteria: 1. caffeine intake \>150 mg per day (i.e. more than one cup of filtered coffee per day) or prescribed adenosine antagonists - caffeine intake will be measured by a standardized intake questionnaire. intake will be converted into estimated caffeine mg dose by standard caffeine-content charts. 2. active peptic ulcer disease, or symptomatic gastroesophageal reflux disease. 3. supraventricular cardiac arrhythmia (such as atrial fibrillation or atrial flutter) - electrocardiogram will be measured at baseline to rule out supraventricular tachycardia. 4. uncontrolled hypertension - systolic bp \>170 or diastolic bp \>110 on two readings. 5. pre-menopausal women who are not using effective methods of birth control 6. cognitive impairment, defined as moca \<23/30. 7. moderate-severe depression, as defined by a beck depression inventory score of \>19. 8. changes to antiparkinsonian medication in the last 3 months, or changes to antiparkinsonian medication are anticipated during the next six months. 9. current use of lithium or clozapine (pharmacokinetic interactions).
fusariosis in solid-organ transplant recipients

Conditions: Solid Organ Transplant; Fusariosis

Summary: this exempt chart review study will try to determine the clinical presentation, prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.

this exempt chart review study will try to determine the clinical presentation, prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.this will help determine prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.

Eligibility criteria:
inclusion criteria: * solid-organ transplants (liver, kidney, lung, heart, pancreas, small bowel transplant) diagnosed with fusariosis or infections due to fusarium, species in our institution exclusion criteria: * those subjects that do not meet inclusion criteria

Keywords: fusariosis solid organ transplants
atherogenic lipoproteins in ischemic stroke

Conditions: Ischemic Stroke

Summary: apolipoprotein b (apob) levels (which encompass all atherogenic lipoproteins, including ldl), lp(a) levels, and carotid iph are associated with both first-ever and recurrent ischemic stroke. this cohort research project is to analyze: 1. among patients with carotid artery atherosclerosis (stenosis 30-99%), to compare patients with and without iph, as assessed by magnetic resonance (mr)-plaque imaging, in terms of apob, lp(a) levels and other cardiovascular risk factors. (iph is a strong morphological sign of plaque vulnerability / instability and a strong marker of consecutive atheroembolic events). 2. among patients with carotid artery atherosclerosis (stenosis 30-99%), to assess the risk of first-ever ischemic stroke in relation to apob, lp(a) levels, and presence of iph, after adjusting for the cardiovascular factors (understanding this association can inform primary prevention). 3. among patients with carotid artery atherosclerosis (stenosis 30-99%) with an ipsilateral ischemic stroke at baseline, to assess the risk of recurrent ipsilateral ischemic stroke in relation to apob, lp(a) levels, and presence of iph, after adjusting for the cardiovascular factors. there will be a sensitivity analysis to assess if the association between lp(a) and recurrent stroke is stronger in patients \<60 years of age. (understanding this association can inform secondary prevention). for the first and second aim, there will be a cross-sectional, case-control analysis. for the third aim, i.e. assessing recurrent ischemic stroke, there is prospective follow-up of at least 3 months up to 45 months.


Eligibility criteria:
inclusion criteria: * atherosclerotic carotid stenosis, north american symptomatic trial collaborators (nascet) method 30-99% * ability to undergo a neck mr for carotid plaque imaging * ability to undergo a follow-up of at least 1-year * for the prospective, longitudinal part: hemispheric ischemic stroke or retinal ischemia ipsilateral to the carotid stenosis, with symptom onset within 24 hours (these patients will be followed-up for recurrent ischemic stroke) exclusion criteria: * carotid stenosis due to causes other than atherosclerosis (e.g. carotid dissection or post-actinic) * contraindication to mri * lack of informed consent

Keywords: apolipoprotein b (apob) lipoprotein(a) (lp(a)) low-density lipoprotein cholesterol (ldl-c) very low-density lipoprotein (vldl) intraplaque hemorrhage (iph) atherogenic lipoproteins dyslipidemia
the implication of ctdna in the recurrence surveillance of stage ii and iii colorectal cancer

Conditions: Colorectal Cancer; ctDNA; Surveillance

Summary: this study is to evaluate circulating tumor dna (ctdna) as a predictive and surveillant method for tumor recurrence in stage ii and iii colorectal cancer (crc).

this study will evaluate circulating tumor dna (ctdna) as a prognostic marker and as a monitor of a short-term disease recurrence in surgical resective stage ii and stage iii colorectal cancer (crc). the investigators will recruit newly diagnosed crc patients, systematically collect their blood samples at the following time point: before surgery, one week after surgery, every three months for the first year and every six months for the second year, which are coincidence with the recommended clinical follow-up. patients' outcome and survival will be tracked. these study will permit assessment of ctdna as a predictive and surveillant method for a short-term (two years) tumor recurrence in comparison with other parameters.

Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age on the day of signing informed consent. * patients must have histologically confirmed stage ii or iiicolorectal cancer. * patients must receive radical resection. * written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. exclusion criteria: * patient has severe anemia. * patients received neoadjuvant treatment. * patients received blood transfusion two weeks before or during the surgical resection. * patient has any other conditions, which, in the opinion of the investigator, would interfere with the evaluation of the subject

Keywords: colorectal cancer ctdna surveillance
pharmacologic mri in cocaine addiction

Conditions: Cocaine Dependence

Summary: in the proposed study, the investigators will assess the brain response to medication probes the investigators have previously studied with spect. the brain response to ondansetron and lidocaine infusions will be measured arterial spin labeling and functional connectivity mri (fcmri).

an extensive effort has been mounted to understand the neurobiologic mechanisms involved in the development and persistence of cocaine addiction and tendency to relapse. although the last two decades have resulted in an explosion in our understanding of the biological mechanisms of reward, establishing the relevance of this knowledge to the addictive process has been problematic. most importantly, this information has been of limited utility in offering new pharmacologic treatment approaches to addicted patients - particularly those with cocaine addiction. over the past 15 years our laboratory has published multiple studies using pharmacologic probes to explore the biologic underpinnings of cocaine addiction using single photon emissions computerized tomography (spect) technology. more recently, however, functional magnetic resonance imaging (fmri) has offered several advantages over spect and is now a favored approach, e.g. fmri allows the continuous measurement of neural responses rather than a very limited time period with spect (1-3 minutes every 48 hours). using fmri \[including both asl (arterial spin labeling) and fcmri (functional connectivity\], the neural response can be measured throughout the 60 min that follows infusion, allowing identification and capture of the maximal brain response period that may occur at any time during this 60 min. in the proposed study, we will assess the brain response to two of the probes (scopolamine and lidocaine) we have previously studied with spect.

Eligibility criteria:
inclusion criteria: * cocaine dependence (cocaine patients) * identify cocaine as their present primary drug of use * patients must have used cocaine within the previous 4 weeks (by patient history) and be abstinent for at least 1 week. * no drug dependence (healthy control population). exclusion criteria: * other medical or psychiatric disorders that may effect neural functioning. * medications that may effect brain functioning

Keywords: cocaine addiction neuroimaging functional magnetic resonance imaging (fmri)
stop vasodepressor drugs in reflex syncope

Conditions: Hypotensive Syncope

Summary: investigate clinical effects (reduction of number of syncope and associate symptoms) of suspension of vasoactive drugs in patients affected by vasodepressor reflex syncope.

several drugs which are commonly used in clinical practice, such as antihypertensive, antiarrhythmic and psychiatric drugs, are associated with orthostatic hypotension and syncope. this phenomenon is much more evident in the elderly and with multiple therapies. the present study was aimed to investigate, in patients affected by reflex syncope, the clinical effects (reduction in syncope recurrence and associated symptoms) and the laboratory tests (negativization of carotid sinus massage and tilt table test) when such drugs are discontinued or reduced

Eligibility criteria:
inclusion criteria: patients assuming chronic (\>1 year) vasoactive therapy affected by reflex recurrent (\>2 episodes) syncopes who have a positive dominant vasodepressor or mixed response to tilt table test and/or carotid sinus massage exclusion criteria: 1. orthostatic hypotension defined as fall in systolic blood pressure \>20 mmhg during the first 3 minutes of active standing 2. competing diagnosis of syncope different from hypotensive reflex syncope 3. reflex syncope with negative response to carotid sinus massage and tilt table test 4. cardioinhibitory reflex syncope which requires permanent cardiac pacing 5. severe hypertension which requires treatment (\>150/95) 6. structured heart disease which requires hypotensive therapy in order to prevent acute heart failure 7. cardiac hypotensive therapy in order to prevent recurrences 8. previous stroke or transient ischemic attacks

Keywords: syncope presyncope vasoactive drugs hypotension carotid sinus massage tilt table test
quantitative ultrasound of trapezius muscle in cervical myofascial syndrome

Conditions: Myofascial Pain Syndrome

Summary: the myofascial points within the trapezius muscle are hypoechogenic regions that can be depicted via ultrasound imaging. in this study we aimed to demonstrate the hypoechogenic regions within the trapezius muscle and to determine if physical therapy modalities change the appearance and size of these areas. we also wanted to explore if the presence of these areas correlate with pain.


Eligibility criteria:
inclusion criteria: * patients with myofascial pain syndrome in the cervical region exclusion criteria: * presence of cervical radiculopathies * previous history of cervical injusy * presence of rheumatologic diseases
reconstructive surgery for head and neck cancer patients

Conditions: Advanced Stage Head and Neck Cancer

Summary: the goal of this study is to better understand the changes in symptoms and overall quality of life after head and neck surgery and reconstruction. "quality of life" means how you feel about your life as a result of your disease and its treatment. learning about changes in patients' quality of life will help doctors and future patients make more informed treatment decisions.

this prospective, longitudinal study will evaluate patient-reported quality of life and symptomatology immediately prior to and for up to one year following surgical resection and reconstruction head and neck malignancies.patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.quality of life and symptom relief will be evaluated by both domain and disease specific questionnaires at four time points: pre-operatively, and 3 months (±1 month), 6 months (±1), and 9 months (-1 and +3) post-operatively. these assessment points represent clinically significant events in patients' post-operative course following head and neck surgery. studies have shown that quality of life decreases significantly at three months after surgery but then reapproaches baseline levels around one year (1). pre-operative responses will serve as the baseline for comparison.

Eligibility criteria:
inclusion criteria: * patients undergoing surgical resection and reconstruction for every stage head and neck malignancies at memorial sloan-kettering cancer center. * patients at least 21 years of age exclusion criteria: * patients who are less than 21 years old * patients who do not speak the english language * patients who are unable to comprehend the content of the questionnaires due to psychiatric disorders or cognitive impairment * patients who cannot complete the pre-operative questionnaires during consent

Keywords: head neck cancer reconstruction quality of life 07-150
clinical-mri evaluation in patients undergoing subtalar arthrorisis with reabsorbable endorthesis implant in plla

Conditions: Lower Limb Deformity

Summary: from the archives of the irccs rizzoli orthopedic institute, all cases of arthrorrhesis of the subtalar joint with a reabsorbable endorthotic implant in plla will be retrieved. an overall electronic database will be created and all medical records of these cases will be reviewed. the eligibility of each individual patient will be assessed on the basis of the exclusion and inclusion criteria (non-probability convenience sampling). the study will not present a control group or comparison groups between therapeutic procedures.


Eligibility criteria:
inclusion criteria: * age between 8 and 15 years at the time of surgery * arthrorrhosis of the subtalar with reabsorbable endorthotic implant in plla * minimum follow-up of 5 years exclusion criteria: * revisions/explantation of the endorthesis device * patients with active acute or chronic infections * patients with chronic inflammatory joint diseases * patients with previous significant trauma of the lower limbs following surgery * patients with pre-existing anomalies of ambulatory kinematics (amputations, neuro-muscular diseases, poliomyelitis, hip dysplasias) * patients with cognitive deficits * - patients with concomitant neurological pathologies * patients suffering from tumor pathology * patients with cardiac pacemakers or other prostheses equipped with electronic circuits * patients with intracranial metal implants, metal heart valves, vascular clips, ferromagnetic endovascular filters/stents/coils, swan-ganz catheters or in any case positioned close to vital anatomical structures * patients with orthopedic metal prostheses * patients with cochlear implants or fixed hearing aids, lens prostheses with ferromagnetic intra-ocular points, iud (coil) or splinters made of ferromagnetic material * pregnant patients * patients with insulin pumps and non-removable contact lenses

Keywords: arthrorrhesis reabsorbable endorthotic implant subtalar joint pediatric joint implant